FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	CG-806 Sensitive: C4 – Case Studies CG-806 Sensitive : C4	CG-806 Sensitive: C4 – Case Studies CG-806 Sensitive : C4

FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation

Associations